Daniela Claudia Moga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniela Claudia Moga has a total of 294 co-authors. Here are the top co-authors by number of shared publications:
- Chris Delcher
University of Kentucky
6 shared publications Erin L. Abner
Sanders-Brown Center on Aging, University of Kentucky, Lexington, USA
6 shared publicationsAshley I. Martinez
Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, USA
5 shared publications- Erin Lynn Abner
University of Kentucky
5 shared publications Gregory A. Jicha
Sanders-Brown Center on Aging, University of Kentucky, Lexington, USA
5 shared publications- Gyeon Oh
Department of Epidemiology and Environmental Health, University of Kentucky, Lexington, USA
5 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in Sleep Health
Bedtime technology activities and multidimensional sleep health in rural Appalachian adults: Findings from the REST-KY study
- 9 October 2026
- Published by Elsevier in Sleep Health
Open AccessBedtime technology activities and multidimensional sleep health in rural Appalachian adults: Findings from the REST-KY study
- Open Access
- 6 July 2026
- Published by Elsevier in Psychiatry Research Communications
- Vol. 6 (3)
Frequent snoring is associated with higher odds of depression in US adults
- 6 July 2026
- Published by Elsevier in Psychiatry Research Communications
- Vol. 6 (3)
Open AccessFrequent snoring is associated with higher odds of depression in US adults
- Open Access
- 17 May 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (6) , e70396
Transportability Analyses in Comparative Effectiveness Research: A Conceptual Framework and Methodological Principles Endorsed by the I nternational S ociety for P harmacoepidemiology
The Problem: Transportability considerations are increasingly important to answer research questions in comparative effectiveness research (CER) to support the transfer of evidence on medicinal products across countries or settings. As drug development costs rise and healthcare systems and professionals face economic and resource pressures, leveraging existing data and evidence generated across borders or settings can improve efficiency and inform decisions in product development and decision‐making (regulatory, health technology assessment [HTA] and clinical care). Differences in population characteristics, healthcare systems, and data availability, including coding discrepancies, may present significant challenges to the transportability of CER evidence. Without rigorous methodological approaches, the utility of transportability analyses is limited. What we Did: This article provides a structured framework for considering transportability exercises in CER analyses. We outlined key methodological principles, when and why to use transportability exercises in CER, feasibility assessments including effect modifier identification and causal inference techniques such as weighting, outcome regression, and combined methods to guide transportability analytical approaches in CER. By synthesizing existing literature and expert insights, we identified opportunities and trade‐offs in applying transportability methods to support decisions across the product lifecycle. Strategies to Disseminate and Facilitate Use: To enhance the adoption of transportability analyses, we proposed best practices for researchers, regulators, HTA bodies, and industry stakeholders. These include early engagement with regulatory agencies and HTA bodies, transparent documentation of data assumptions, quality, fitness, and comparability assessments while ensuring robust analytical approaches. We also emphasized the need for standardized reporting guidelines and cross‐country collaborations to validate transportability methods in real‐world settings and communicate uncertainty in transported evidence. Conclusions: Transportability analyses offer a powerful tool for extending the applicability of CER findings across healthcare systems, improving evidence generation efficiency, and supporting global drug development and evaluation. By implementing best practices that promote a rigorous and transparent approach to the design and conduct of such analyses, stakeholders can maximize the value of transported treatment effects while ensuring scientific rigor and decision‐making relevance. Future research should focus on empirical testing and validation of transportability methods targeting different questions across the product lifecycle and the development of harmonized regulatory and HTA methodological standards. “This manuscript is endorsed by the International Society for Pharmacoepidemiology (ISPE).” Official Endorsement was received on 5/13/26.
- 17 May 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (6) , e70396
Open AccessTransportability Analyses in Comparative Effectiveness Research: A Conceptual Framework and Methodological Principles Endorsed by the I nternational S ociety for P harmacoepidemiology
The Problem: Transportability considerations are increasingly important to answer research questions in comparative effectiveness research (CER) to support the transfer of evidence on medicinal products across countries or settings. As drug development costs rise and healthcare systems and professionals face economic and resource pressures, leveraging existing data and evidence generated across borders or settings can improve efficiency and inform decisions in product development and decision‐making (regulatory, health technology assessment [HTA] and clinical care). Differences in population characteristics, healthcare systems, and data availability, including coding discrepancies, may present significant challenges to the transportability of CER evidence. Without rigorous methodological approaches, the utility of transportability analyses is limited. What we Did: This article provides a structured framework for considering transportability exercises in CER analyses. We outlined key methodological principles, when and why to use transportability exercises in CER, feasibility assessments including effect modifier identification and causal inference techniques such as weighting, outcome regression, and combined methods to guide transportability analytical approaches in CER. By synthesizing existing literature and expert insights, we identified opportunities and trade‐offs in applying transportability methods to support decisions across the product lifecycle. Strategies to Disseminate and Facilitate Use: To enhance the adoption of transportability analyses, we proposed best practices for researchers, regulators, HTA bodies, and industry stakeholders. These include early engagement with regulatory agencies and HTA bodies, transparent documentation of data assumptions, quality, fitness, and comparability assessments while ensuring robust analytical approaches. We also emphasized the need for standardized reporting guidelines and cross‐country collaborations to validate transportability methods in real‐world settings and communicate uncertainty in transported evidence. Conclusions: Transportability analyses offer a powerful tool for extending the applicability of CER findings across healthcare systems, improving evidence generation efficiency, and supporting global drug development and evaluation. By implementing best practices that promote a rigorous and transparent approach to the design and conduct of such analyses, stakeholders can maximize the value of transported treatment effects while ensuring scientific rigor and decision‐making relevance. Future research should focus on empirical testing and validation of transportability methods targeting different questions across the product lifecycle and the development of harmonized regulatory and HTA methodological standards. “This manuscript is endorsed by the International Society for Pharmacoepidemiology (ISPE).” Official Endorsement was received on 5/13/26.
- 20 April 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (4) , e70381
Comparative Cardiovascular Safety of Prescription Amphetamine and Methylphenidate Initiation Among Older Adult Medicare Beneficiaries
Background: Prescription stimulant use among the United States' (US) older adult population is increasing, yet little is known about the cardiovascular safety profiles of the two major prescription stimulant classes, methylphenidate (MPD) and amphetamine (AMP). Objective: To compare the hazard of major adverse cardiovascular (CV) events between new users of prescription MPD and AMP products in US older adults. Methods: We employed a new user comparative safety study from a 5% random sample of fee‐for‐service Medicare beneficiaries. Continuously enrolled beneficiaries (Parts A/B/D) aged ≥ 66 years who initiated MPD or AMP (1/1/17–12/31/21) were included. We required a 1‐year washout before the first prescription claim (index date) and excluded those with contraindications based on diagnosis codes. The primary outcome was incident modified 4‐Point Major Adverse Cardiovascular Event (4‐P MACE), including acute myocardial infarction, stroke or transient ischemic attack, ventricular arrhythmia, or all‐cause mortality; secondary outcomes included all‐cause mortality and CV events (all MACE excluding death). We used a 1‐year follow up after index date that was censored at change in insurance coverage, therapeutic switch, addition of the comparator drug, or end of the study (12/31/21). Confounders included demographics, healthcare utilization indicators, comorbidities, and other medications. We used trimmed propensity scores (PS) to create stabilized inverse probability of treatment weights (IPTW) and Cox proportional hazard regression to estimate the effect of MPD vs. AMP initiation on the first occurrence of 4‐P MACE. Results: We identified 2526 Medicare beneficiaries initiating MPD ( N = 1340, mean [SD] age = 76.7 [7.4] years, 54.3% female sex) or AMP ( N = 1186, mean [SD] age = 72.3 [5.4] years, 60.6% female sex). After PS trimming and applying IPTW, the groups were well‐balanced based on absolute standardized mean differences. During 2021.6 person‐years follow up (MPD [1009.9 years] vs. AMP [1011.8 years]), 339 4‐P MACE events occurred (MPD [ N = 280] vs. AMP [ N = 59]), of which 225 were deaths (MPD [ N = 192] vs. AMP [ N = 33]), and 114 were CV events (MPD [ N = 88] vs. AMP [ N = 26]). In the primary analysis, MPD vs. AMP initiation was associated with an increased risk of 4‐P MACE (HR = 1.73, 95% CI [1.36, 2.19]). The secondary analysis showed a statistically significant increased risk of all‐cause mortality (HR = 2.20, 95% CI [1.62, 3.00]), but not adverse CV events (HR = 1.14, 95% CI [0.77, 1.67]). Conclusions: Initiation of MPD vs. AMP among older adults was associated with an increase in the hazard of 4‐P MACE. Secondary analysis suggested that this increase was driven by all‐cause mortality as opposed to adverse CV events.
- 20 April 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (4) , e70381
Comparative Cardiovascular Safety of Prescription Amphetamine and Methylphenidate Initiation Among Older Adult Medicare Beneficiaries
Background: Prescription stimulant use among the United States' (US) older adult population is increasing, yet little is known about the cardiovascular safety profiles of the two major prescription stimulant classes, methylphenidate (MPD) and amphetamine (AMP). Objective: To compare the hazard of major adverse cardiovascular (CV) events between new users of prescription MPD and AMP products in US older adults. Methods: We employed a new user comparative safety study from a 5% random sample of fee‐for‐service Medicare beneficiaries. Continuously enrolled beneficiaries (Parts A/B/D) aged ≥ 66 years who initiated MPD or AMP (1/1/17–12/31/21) were included. We required a 1‐year washout before the first prescription claim (index date) and excluded those with contraindications based on diagnosis codes. The primary outcome was incident modified 4‐Point Major Adverse Cardiovascular Event (4‐P MACE), including acute myocardial infarction, stroke or transient ischemic attack, ventricular arrhythmia, or all‐cause mortality; secondary outcomes included all‐cause mortality and CV events (all MACE excluding death). We used a 1‐year follow up after index date that was censored at change in insurance coverage, therapeutic switch, addition of the comparator drug, or end of the study (12/31/21). Confounders included demographics, healthcare utilization indicators, comorbidities, and other medications. We used trimmed propensity scores (PS) to create stabilized inverse probability of treatment weights (IPTW) and Cox proportional hazard regression to estimate the effect of MPD vs. AMP initiation on the first occurrence of 4‐P MACE. Results: We identified 2526 Medicare beneficiaries initiating MPD ( N = 1340, mean [SD] age = 76.7 [7.4] years, 54.3% female sex) or AMP ( N = 1186, mean [SD] age = 72.3 [5.4] years, 60.6% female sex). After PS trimming and applying IPTW, the groups were well‐balanced based on absolute standardized mean differences. During 2021.6 person‐years follow up (MPD [1009.9 years] vs. AMP [1011.8 years]), 339 4‐P MACE events occurred (MPD [ N = 280] vs. AMP [ N = 59]), of which 225 were deaths (MPD [ N = 192] vs. AMP [ N = 33]), and 114 were CV events (MPD [ N = 88] vs. AMP [ N = 26]). In the primary analysis, MPD vs. AMP initiation was associated with an increased risk of 4‐P MACE (HR = 1.73, 95% CI [1.36, 2.19]). The secondary analysis showed a statistically significant increased risk of all‐cause mortality (HR = 2.20, 95% CI [1.62, 3.00]), but not adverse CV events (HR = 1.14, 95% CI [0.77, 1.67]). Conclusions: Initiation of MPD vs. AMP among older adults was associated with an increase in the hazard of 4‐P MACE. Secondary analysis suggested that this increase was driven by all‐cause mortality as opposed to adverse CV events.
- Open Access
- 26 March 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (4) , e70351
Curriculum in Pharmacoepidemiology Training Programs: A Cross‐Sectional Study to Assess Educational Needs and Alignment With Core Competencies
Purpose: Pharmacoepidemiology is a key discipline for evidence‐based decision‐making, yet its educational programs have not been systematically assessed for alignment with international core competencies. Our objectives were to evaluate curricula alignment of pharmacoepidemiology training programs with ISPE‐recommended core competency themes and identify key curriculum content development areas. Methods: The ISPE Core Competencies Workgroup and ISPE leadership developed a curriculum and needs assessment survey, incorporating feedback from global members. The survey was electronically distributed to leaders of pharmacoepidemiology training programs (e.g., department chairs and program directors) using the ISPE contact database, followed by snowball sampling to enhance representation. Institutional respondent characteristics were categorized by sector and geographic region. Competency mapping identified the most and least represented competency categories within curricula. Needs assessment responses were reported as proportions, and free‐text responses were thematically analyzed, allowing for multiple themes per response. Results: Sixty‐four institutions participated (73.4% academic programs, 18.8% industry/consulting, and 7.8% government/regulatory). Representation by global region was: 35.9% Europe, 29.7% North America, 23.4% Latin America, 7.8% Asia, 1.6% Africa, and 1.6% Gulf Region. Respondents prioritized developing standards in pharmacoepidemiology training curriculum in two areas—45.5% “Epidemiology” and 36.4% “Statistics, Analysis, and Data Science”—with few endorsements of other areas. The most represented competencies covered in curricula were “Statistics” (100%, 45/45) and “Study Design” (100%, 43/43). The least represented were “Advanced Modeling” (54%, 25/46) and “Professional Practice” (66%, 31/47). Key needs in pharmacoepidemiology curriculum centered around four themes: 33.3% (8/24) “Methods (generally)”, 33.3% (8/24) “Analytical Skills,” 16.7% (4/24) “Communication (writing, teaching),” and 25.0% “(6/24) Other (applications, new therapies).” Content type that would best support curriculum development, as ranked by 42 respondents, was: “Learning objectives with pre‐packaged activities” 45.2% (19/42), “Recorded webinars/lectures” 28.6% (12/42), “Example syllabi” 21.4% (9/42), and “Reading lists” 4.8% (2/42). Conclusions: This global assessment highlights critical gaps in pharmacoepidemiology training, particularly in advanced analytical methods and professional practice. ISPE has a unique opportunity to address these gaps by developing targeted educational activities and resources that enhance methodological rigor and practical skills.
- 26 March 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (4) , e70351
Open AccessCurriculum in Pharmacoepidemiology Training Programs: A Cross‐Sectional Study to Assess Educational Needs and Alignment With Core Competencies
Purpose: Pharmacoepidemiology is a key discipline for evidence‐based decision‐making, yet its educational programs have not been systematically assessed for alignment with international core competencies. Our objectives were to evaluate curricula alignment of pharmacoepidemiology training programs with ISPE‐recommended core competency themes and identify key curriculum content development areas. Methods: The ISPE Core Competencies Workgroup and ISPE leadership developed a curriculum and needs assessment survey, incorporating feedback from global members. The survey was electronically distributed to leaders of pharmacoepidemiology training programs (e.g., department chairs and program directors) using the ISPE contact database, followed by snowball sampling to enhance representation. Institutional respondent characteristics were categorized by sector and geographic region. Competency mapping identified the most and least represented competency categories within curricula. Needs assessment responses were reported as proportions, and free‐text responses were thematically analyzed, allowing for multiple themes per response. Results: Sixty‐four institutions participated (73.4% academic programs, 18.8% industry/consulting, and 7.8% government/regulatory). Representation by global region was: 35.9% Europe, 29.7% North America, 23.4% Latin America, 7.8% Asia, 1.6% Africa, and 1.6% Gulf Region. Respondents prioritized developing standards in pharmacoepidemiology training curriculum in two areas—45.5% “Epidemiology” and 36.4% “Statistics, Analysis, and Data Science”—with few endorsements of other areas. The most represented competencies covered in curricula were “Statistics” (100%, 45/45) and “Study Design” (100%, 43/43). The least represented were “Advanced Modeling” (54%, 25/46) and “Professional Practice” (66%, 31/47). Key needs in pharmacoepidemiology curriculum centered around four themes: 33.3% (8/24) “Methods (generally)”, 33.3% (8/24) “Analytical Skills,” 16.7% (4/24) “Communication (writing, teaching),” and 25.0% “(6/24) Other (applications, new therapies).” Content type that would best support curriculum development, as ranked by 42 respondents, was: “Learning objectives with pre‐packaged activities” 45.2% (19/42), “Recorded webinars/lectures” 28.6% (12/42), “Example syllabi” 21.4% (9/42), and “Reading lists” 4.8% (2/42). Conclusions: This global assessment highlights critical gaps in pharmacoepidemiology training, particularly in advanced analytical methods and professional practice. ISPE has a unique opportunity to address these gaps by developing targeted educational activities and resources that enhance methodological rigor and practical skills.
- Open Access
- 1 March 2026
- Published by Wiley in The Journal of Rural Health
- Vol. 42 (2) , e70160
Contraceptive Method Provision Patterns Among Rural and Urban Kentucky Medicaid Enrollees
Purpose: To characterize contraceptive provision among the Kentucky Medicaid population and assess for rural−urban disparities. Methods: Kentucky Medicaid claims from the calendar year 2019 were used to identify females at risk for unintended pregnancy (via a modified version of the criteria defined by the US Department of Health and Human Services Office of Population Affairs). Multinomial logistic regression was used to assess the impact of rural−urban residence on contraceptive outcomes, while adjusting for relevant covariates. Outcomes for the multinomial regression model were provision of a: (1) less effective method (i.e., condoms) or no contraceptive; (2) moderately effective method (oral, transdermal, injectable, or vaginal); (3) or long‐acting reversible contraceptive (LARC) method. Findings: A total of 239,160 enrollees at risk for unintended pregnancy were included for analyses. Adjusted odds of provision of a moderately effective method (vs. a less effective method or no method) were higher among both those residing in rural‐adjacent to urban (aOR 1.17; 95% CI, 1.13–1.20) and rural‐nonadjacent to urban (aOR 1.15; 95% CI, 1.12–1.18) locations compared to urban. Notably, adjusted odds of provision of an LARC method (vs. a less effective method or no method) were significantly lower among those residing in rural‐nonadjacent to urban locations (aOR 0.81; 95% CI 0.77–0.85) compared to those in urban locations. Conclusions: Despite high moderately effective contraceptive provision among Kentucky Medicaid enrollees in rural‐nonadjacent to urban counties, adjusted odds of LARC provision are significantly lower, signaling significant barriers to access among this population.
- 1 March 2026
- Published by Wiley in The Journal of Rural Health
- Vol. 42 (2) , e70160
Open AccessContraceptive Method Provision Patterns Among Rural and Urban Kentucky Medicaid Enrollees
Purpose: To characterize contraceptive provision among the Kentucky Medicaid population and assess for rural−urban disparities. Methods: Kentucky Medicaid claims from the calendar year 2019 were used to identify females at risk for unintended pregnancy (via a modified version of the criteria defined by the US Department of Health and Human Services Office of Population Affairs). Multinomial logistic regression was used to assess the impact of rural−urban residence on contraceptive outcomes, while adjusting for relevant covariates. Outcomes for the multinomial regression model were provision of a: (1) less effective method (i.e., condoms) or no contraceptive; (2) moderately effective method (oral, transdermal, injectable, or vaginal); (3) or long‐acting reversible contraceptive (LARC) method. Findings: A total of 239,160 enrollees at risk for unintended pregnancy were included for analyses. Adjusted odds of provision of a moderately effective method (vs. a less effective method or no method) were higher among both those residing in rural‐adjacent to urban (aOR 1.17; 95% CI, 1.13–1.20) and rural‐nonadjacent to urban (aOR 1.15; 95% CI, 1.12–1.18) locations compared to urban. Notably, adjusted odds of provision of an LARC method (vs. a less effective method or no method) were significantly lower among those residing in rural‐nonadjacent to urban locations (aOR 0.81; 95% CI 0.77–0.85) compared to those in urban locations. Conclusions: Despite high moderately effective contraceptive provision among Kentucky Medicaid enrollees in rural‐nonadjacent to urban counties, adjusted odds of LARC provision are significantly lower, signaling significant barriers to access among this population.
- Open Access
- 14 November 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (11) , e70255
The Reporting and Methodological Recommendations for Observational Studies Estimating the Effects of Deprescribing Medications (REMROSE‐D) ISPE‐Endorsed Guidance
Purpose: Pharmacoepidemiologic studies on deprescribing are challenging to implement, yet little guidance exists on methods to avoid bias and minimum reporting for replicability and appraisal. We developed consensus recommendations for the methods and reporting of observational studies that aim to examine the effects of deprescribing. Methods: We formed candidate recommendations based on our prior systematic review that methodologically appraised observational studies on deprescribing. We then conducted a two‐round modified Delphi process with researchers working in deprescribing pharmacoepidemiology to refine, select, and reach consensus on recommendations for a checklist based on > 70% agreement of their importance. We termed this list the REMROSE‐D (Reporting and Methodological Recommendations for Observational Studies estimating the Effects of Deprescribing medications) guidance. Results: Twenty‐three candidate recommendations were presented to the Delphi panel. The round 1 survey was completed by 55 participants, and 18 of the 23 candidate recommendations were selected for inclusion. Five candidate recommendations without consensus plus two additional items suggested by participants were included in a round 2 survey of 25 deprescribing researchers. Five of these seven items garnered consensus for inclusion, and two were excluded. The final REMROSE‐D guidance contains 23 recommendations for the methods and reporting of observational research on deprescribing. Conclusion: To ensure rigor and reproducibility in observational studies of the effects of deprescribing, the REMROSE‐D guidance provides recommendations for important reporting and methods considerations, including time zero, precise definitions of deprescribing, addressing confounding by indication, and careful consideration of follow‐up to avoid immortal time bias.
- 14 November 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (11) , e70255
Open AccessThe Reporting and Methodological Recommendations for Observational Studies Estimating the Effects of Deprescribing Medications (REMROSE‐D) ISPE‐Endorsed Guidance
Purpose: Pharmacoepidemiologic studies on deprescribing are challenging to implement, yet little guidance exists on methods to avoid bias and minimum reporting for replicability and appraisal. We developed consensus recommendations for the methods and reporting of observational studies that aim to examine the effects of deprescribing. Methods: We formed candidate recommendations based on our prior systematic review that methodologically appraised observational studies on deprescribing. We then conducted a two‐round modified Delphi process with researchers working in deprescribing pharmacoepidemiology to refine, select, and reach consensus on recommendations for a checklist based on > 70% agreement of their importance. We termed this list the REMROSE‐D (Reporting and Methodological Recommendations for Observational Studies estimating the Effects of Deprescribing medications) guidance. Results: Twenty‐three candidate recommendations were presented to the Delphi panel. The round 1 survey was completed by 55 participants, and 18 of the 23 candidate recommendations were selected for inclusion. Five candidate recommendations without consensus plus two additional items suggested by participants were included in a round 2 survey of 25 deprescribing researchers. Five of these seven items garnered consensus for inclusion, and two were excluded. The final REMROSE‐D guidance contains 23 recommendations for the methods and reporting of observational research on deprescribing. Conclusion: To ensure rigor and reproducibility in observational studies of the effects of deprescribing, the REMROSE‐D guidance provides recommendations for important reporting and methods considerations, including time zero, precise definitions of deprescribing, addressing confounding by indication, and careful consideration of follow‐up to avoid immortal time bias.
- Open Access
- 20 August 2025
- Published by Wiley
Comparative Cardiovascular Safety of Prescription Amphetamine and Methylphenidate Initiation Among Older Adult Medicare Beneficiaries
Background: Prescription stimulant use among the United States’ (US) older adult population is increasing, yet little is known about the cardiovascular safety profiles of the two major prescription stimulant classes, methylphenidate (MPD) and amphetamine (AMP). Objective: To compare the hazard of major adverse cardiovascular (CV) events between new users of prescription MPD and AMP products in US older adults. Methods: We employed a new-user comparative safety study from a 5% random sample of fee-for-service Medicare beneficiaries. Continuously enrolled beneficiaries (Parts A/B/D) aged ≥66 years who initiated MPD or AMP (1/1/17 - 12/31/21) were included. We required a 1-year washout before the first prescription claim (index date) and excluded those with contraindications based on diagnosis codes. The primary outcome was incident 4-P MACE (modified 4-point major adverse CV event, including acute myocardial infarction, stroke or transient ischemic attack, ventricular arrhythmia, and all-cause mortality); secondary outcomes included mortality and CV events (all MACE excluding death). We used a 1-year follow up after index date that was censored at change in insurance coverage, therapeutic switch, addition of the comparator drug, or end of the study (12/31/21). Confounders included demographics, healthcare utilization indicators, comorbidities, and other medications. We used trimmed propensity scores (PS) to create stabilized inverse probability of treatment weights (IPTW) and Cox proportional hazard regression to estimate the effect of MPD vs. AMP initiation on the first occurrence of 4-P MACE. Results: We identified 2526 Medicare beneficiaries initiating MPD (N=1340, mean [SD] age=74.5 [6.4] years, 56.3% female sex) or AMP (N=1186, mean [SD] age=74.7 [6.6] years, 55.7% female sex). After PS trimming and applying IPTW, the groups were well-balanced based on absolute standardized mean differences. During 2021.6 person-years follow up (MPD [1009.9 years] vs. AMP [1011.8 years]), 339 4-P MACE events occurred (MPD [N=280] vs. AMP [N=59]), of which 225 were deaths (MPD [N=192] vs. AMP [N=33]), and 114 were CV events (MPD [N=88] vs. AMP [N=26]). In the primary analysis, MPD vs. AMP initiation was associated with an increased risk of 4-P MACE (HR = 1.73, 95% CI [1.36, 2.19]). The secondary analysis showed a statistically significant increased risk of mortality (HR = 2.20, 95% CI [1.62, 3.00]), but not CV events (HR = 1.14, 95% CI [0.77, 1.67]). Conclusions: Initiation of MPD vs. AMP among older adults was associated with an increase in the hazard of 4-P MACE. Secondary analysis suggested that this increase was driven by mortality as opposed to CV events.
- 20 August 2025
- Published by Wiley
Open AccessComparative Cardiovascular Safety of Prescription Amphetamine and Methylphenidate Initiation Among Older Adult Medicare Beneficiaries
Background: Prescription stimulant use among the United States’ (US) older adult population is increasing, yet little is known about the cardiovascular safety profiles of the two major prescription stimulant classes, methylphenidate (MPD) and amphetamine (AMP). Objective: To compare the hazard of major adverse cardiovascular (CV) events between new users of prescription MPD and AMP products in US older adults. Methods: We employed a new-user comparative safety study from a 5% random sample of fee-for-service Medicare beneficiaries. Continuously enrolled beneficiaries (Parts A/B/D) aged ≥66 years who initiated MPD or AMP (1/1/17 - 12/31/21) were included. We required a 1-year washout before the first prescription claim (index date) and excluded those with contraindications based on diagnosis codes. The primary outcome was incident 4-P MACE (modified 4-point major adverse CV event, including acute myocardial infarction, stroke or transient ischemic attack, ventricular arrhythmia, and all-cause mortality); secondary outcomes included mortality and CV events (all MACE excluding death). We used a 1-year follow up after index date that was censored at change in insurance coverage, therapeutic switch, addition of the comparator drug, or end of the study (12/31/21). Confounders included demographics, healthcare utilization indicators, comorbidities, and other medications. We used trimmed propensity scores (PS) to create stabilized inverse probability of treatment weights (IPTW) and Cox proportional hazard regression to estimate the effect of MPD vs. AMP initiation on the first occurrence of 4-P MACE. Results: We identified 2526 Medicare beneficiaries initiating MPD (N=1340, mean [SD] age=74.5 [6.4] years, 56.3% female sex) or AMP (N=1186, mean [SD] age=74.7 [6.6] years, 55.7% female sex). After PS trimming and applying IPTW, the groups were well-balanced based on absolute standardized mean differences. During 2021.6 person-years follow up (MPD [1009.9 years] vs. AMP [1011.8 years]), 339 4-P MACE events occurred (MPD [N=280] vs. AMP [N=59]), of which 225 were deaths (MPD [N=192] vs. AMP [N=33]), and 114 were CV events (MPD [N=88] vs. AMP [N=26]). In the primary analysis, MPD vs. AMP initiation was associated with an increased risk of 4-P MACE (HR = 1.73, 95% CI [1.36, 2.19]). The secondary analysis showed a statistically significant increased risk of mortality (HR = 2.20, 95% CI [1.62, 3.00]), but not CV events (HR = 1.14, 95% CI [0.77, 1.67]). Conclusions: Initiation of MPD vs. AMP among older adults was associated with an increase in the hazard of 4-P MACE. Secondary analysis suggested that this increase was driven by mortality as opposed to CV events.
- Open Access
- 20 July 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (7) , e70175
Advancing Health Equity in Europe: Explore, Tailor, Implement, and Evaluate (ETIE)—A Framework of Diversity and Fairness in Pharmacoepidemiologic Research
Pharmacoepidemiology should represent and benefit populations equitably, embracing diversity and equity, and ensuring fairness. This article describes equity and fairness in pharmacoepidemiology, depicts key diversity domains, and provides an operational framework and call for action to implement diversity and fairness in pharmacoepidemiologic research. To ensure fairness, studies should address diversity and inclusion while providing equal opportunities and benefits for everyone in the target population. To implement and evaluate fairness in pharmacoepidemiology, we defined the following diversity domains: biological sex, socially constructed gender, age, life stages (e.g., pregnancy, menopause), ethnicity, race, migration, nationality, socioeconomic status, education, health literacy, and health status and capabilities. These are determinants of health, either through biological pathways or through social norms, discrimination, and barriers to healthcare or research participation. They are interlinked, their impact is study‐ and context‐specific, and due to their sensitive and evolving nature, they should be handled with caution. Implementing diversity domains enables researchers to assess the generalizability of findings, identify and address health inequities, account for determinants of health, and ensure the fairness of algorithms, implementations, and recommendations. To successfully implement diversity domains and ensure fair pharmacoepidemiologic research, we recommend researchers to follow the Explore, Tailor, Implement, and Evaluate (ETIE) framework: Explore the role/implication of the diversity domains in the study, tailor their definitions to the study context, implement them appropriately and evaluate the study findings in their context. Increased availability of diversity data is needed, and support from stakeholders is essential. This manuscript was endorsed by the International Society for Pharmacoepidemiology (ISPE).
- 20 July 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (7) , e70175
Open AccessAdvancing Health Equity in Europe: Explore, Tailor, Implement, and Evaluate (ETIE)—A Framework of Diversity and Fairness in Pharmacoepidemiologic Research
Pharmacoepidemiology should represent and benefit populations equitably, embracing diversity and equity, and ensuring fairness. This article describes equity and fairness in pharmacoepidemiology, depicts key diversity domains, and provides an operational framework and call for action to implement diversity and fairness in pharmacoepidemiologic research. To ensure fairness, studies should address diversity and inclusion while providing equal opportunities and benefits for everyone in the target population. To implement and evaluate fairness in pharmacoepidemiology, we defined the following diversity domains: biological sex, socially constructed gender, age, life stages (e.g., pregnancy, menopause), ethnicity, race, migration, nationality, socioeconomic status, education, health literacy, and health status and capabilities. These are determinants of health, either through biological pathways or through social norms, discrimination, and barriers to healthcare or research participation. They are interlinked, their impact is study‐ and context‐specific, and due to their sensitive and evolving nature, they should be handled with caution. Implementing diversity domains enables researchers to assess the generalizability of findings, identify and address health inequities, account for determinants of health, and ensure the fairness of algorithms, implementations, and recommendations. To successfully implement diversity domains and ensure fair pharmacoepidemiologic research, we recommend researchers to follow the Explore, Tailor, Implement, and Evaluate (ETIE) framework: Explore the role/implication of the diversity domains in the study, tailor their definitions to the study context, implement them appropriately and evaluate the study findings in their context. Increased availability of diversity data is needed, and support from stakeholders is essential. This manuscript was endorsed by the International Society for Pharmacoepidemiology (ISPE).
- 16 May 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (5) , e70159
Changes in Hormonal Contraceptive Dispensing Trends Among Commercially Insured Kentucky Females During the COVID‐19 Pandemic
Purpose: To evaluate the impact of the COVID‐19 national emergency declaration on contraceptive dispensing trends among commercially insured Kentucky females.Methods: Data ranging from 1/7/2019 through 12/27/2020 for female enrollees aged 19–44 with a primary residence in Kentucky were extracted from the Merative Marketscan Commercial Claims and Encounters Database. A segmented regression analysis was used for statistical modeling of an interrupted time series design to describe changes in weekly contraceptive (oral, transdermal, and vaginal) dispensing rates and days' supply following the COVID‐19 national emergency.Results: A total of 90 541 enrollees met study inclusion criteria. The estimated weekly contraceptive dispensing rate per 100 reproductive‐aged female enrollees was 3.22 (95% confidence interval [CI] 3.16–3.28) at the beginning of the pre‐pandemic period. Following the national emergency, an immediate estimated rate increase of 0.11 (95% CI 0.01–0.21; p = 0.030) was seen with no change in trend. At the beginning of the pre‐pandemic period, the estimated weekly percentage of days' supply > 28 days was 29.2% (95% CI 28.8–29.6) with an increasing trend of 1.1% every 10 weeks (slope 0.11 [95% CI 0.09–0.12; p < 0.001]). Following the national emergency, an immediate decrease of 1.5% (95% CI −2.2 to −0.8; p < 0.001) was observed, followed by sustainment of the pre‐pandemic trend. No differential impacts were seen with regard to age group (19–26 vs. 27–44) or rural–urban classification.Conclusions: Following the COVID‐19 national emergency declaration, trends in both contraceptive dispensing and days' supply among commercially insured Kentucky females were relatively stable, suggesting multiple behavioral and policy‐related factors potentially overshadowing changes in access.
- 16 May 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (5) , e70159
Changes in Hormonal Contraceptive Dispensing Trends Among Commercially Insured Kentucky Females During the COVID‐19 Pandemic
Purpose: To evaluate the impact of the COVID‐19 national emergency declaration on contraceptive dispensing trends among commercially insured Kentucky females.Methods: Data ranging from 1/7/2019 through 12/27/2020 for female enrollees aged 19–44 with a primary residence in Kentucky were extracted from the Merative Marketscan Commercial Claims and Encounters Database. A segmented regression analysis was used for statistical modeling of an interrupted time series design to describe changes in weekly contraceptive (oral, transdermal, and vaginal) dispensing rates and days' supply following the COVID‐19 national emergency.Results: A total of 90 541 enrollees met study inclusion criteria. The estimated weekly contraceptive dispensing rate per 100 reproductive‐aged female enrollees was 3.22 (95% confidence interval [CI] 3.16–3.28) at the beginning of the pre‐pandemic period. Following the national emergency, an immediate estimated rate increase of 0.11 (95% CI 0.01–0.21; p = 0.030) was seen with no change in trend. At the beginning of the pre‐pandemic period, the estimated weekly percentage of days' supply > 28 days was 29.2% (95% CI 28.8–29.6) with an increasing trend of 1.1% every 10 weeks (slope 0.11 [95% CI 0.09–0.12; p < 0.001]). Following the national emergency, an immediate decrease of 1.5% (95% CI −2.2 to −0.8; p < 0.001) was observed, followed by sustainment of the pre‐pandemic trend. No differential impacts were seen with regard to age group (19–26 vs. 27–44) or rural–urban classification.Conclusions: Following the COVID‐19 national emergency declaration, trends in both contraceptive dispensing and days' supply among commercially insured Kentucky females were relatively stable, suggesting multiple behavioral and policy‐related factors potentially overshadowing changes in access.